The financing needs of the biotech industry leave it particularly vulnerable to securities fraud claims, as companies with no products or earnings seek the attention of Wall Street through projections of future events.

As Larry Sonsini, chairman of Wilson Sonsini Goodrich & Rosati, told a San Francisco seminar last week, the problem is, "by definition, most projections are wrong - you either overshoot or undershoot."